New Features in Screening of Retinopathy of Prematurity. Our Experience with New Recommendations for Retinopathy of Prematurity Screening
Authors:
Dana Tomčíková; Zuzana Prepiaková; Beáta Bušányová; Barbora Kostolná
Authors‘ workplace:
University and the National Institute of Children’s Diseases, Bratislava, Slovakia
; Department of Pediatric Ophthalmology, Faculty of Medicine of Comenius
Published in:
Čes. a slov. Oftal., 81, 2025, No. Ahead of Print, p. 1-5
Category:
Original Article
doi:
https://doi.org/10.31348/2025/23
Overview
Retinopathy of prematurity (ROP) is always a serious and sight-threatening condition, and its treatable stages require early detection and adequate treatment. It is necessary to focus on the principles of screening of ROP and recurrences thereof, which occur more often with the onset of intravitreal treatment using anti-vascular endothelial growth factor (anti-VEGF) agents. In this study, we evaluate the recurrence of ROP after primary treatment with intravitreally administered bevacizumab or ranibizumab, its frequency and timing of occurrence. Also discussed are the rules for screening of ROP, its recurrence and the need for long-term follow-up monitoring of children with any form of ROP.
Keywords:
recurrence of ROP – ROP recurrence screening – intravitreal treatment of ROP – follow-up monitoring of premature infants with ROP – ROP screening
Labels
OphthalmologyArticle was published in
Czech and Slovak Ophthalmology

2025 Issue Ahead of Print
Most read in this issue
- Easy Method of Pterygium Excision using Autologous Blood for Conjunctiva Autograft Fixation
- Two-year results of Preserflo Microshunt use in Open-angle Glaucoma Surgery
- Treatment of Patients with Central Serous Chorioretinopathy using Navigated Laser Photocoagulation
- Vessel density and retinal nerve fiber layer in pathological intraocular pressure